Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

NCT04448834 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study not moving forward

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

Dorothy Sipkins, MD, PhD

Collaborators

[object Object]
[object Object]